What's in Athenex, Inc.'s pipeline?

Athenex, Inc. has 6 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 1 in Phase 2, 3 in Phase 1.

Which companies overlap with Athenex, Inc.'s portfolio?

Top competitors by shared drug class: Akeso, Aravive, Inc., Barts & The London NHS Trust, BeyondSpring Pharmaceuticals Inc., Bio-Thera Solutions.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/athenex-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-13 · How we verify

Athenex, Inc. — Portfolio Competitive Intelligence Brief

Athenex, Inc. pipeline: 0 marketed, 0 filed, 1 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 1 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
IV paclitaxel	IV paclitaxel	phase 3	Taxane; microtubule stabilizer	β-tubulin	Oncology

Therapeutic area mix

Other · 4
Oncology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Akeso · 1 shared drug class
Aravive, Inc. · 1 shared drug class
Barts & The London NHS Trust · 1 shared drug class
BeyondSpring Pharmaceuticals Inc. · 1 shared drug class
Bio-Thera Solutions · 1 shared drug class
Dai, Guanghai · 1 shared drug class
Fujian Medical University · 1 shared drug class
Guangzhou Double Bioproducts Co., Ltd · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Athenex, Inc.:

Cite this brief

Drug Landscape (2026). Athenex, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/athenex-inc. Accessed 2026-05-13.